Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells
•We study the anti-ostoclastogenesis effect of SG in RANKL-activated RAW 264.7 cells.•SG inhibits osteoclastogenesis from macrophages in vitro.•SG also reduced the RANKL-induced expression of osteoclastic marker genes.•Moreover, SG attenuated RANKL-induced MAPKs and NF-κB activation. Inflammatory cy...
Gespeichert in:
| Veröffentlicht in: | Biochemical and biophysical research communications 2013-05, Vol.434 (4), p.892-897 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 897 |
|---|---|
| container_issue | 4 |
| container_start_page | 892 |
| container_title | Biochemical and biophysical research communications |
| container_volume | 434 |
| creator | Yoon, Weon-Jong Kim, Kil-Nam Heo, Soo-Jin Han, Sang-Chul Kim, Jihyeon Ko, Yeong-Jong Kang, Hee-Kyoung Yoo, Eun-Sook |
| description | •We study the anti-ostoclastogenesis effect of SG in RANKL-activated RAW 264.7 cells.•SG inhibits osteoclastogenesis from macrophages in vitro.•SG also reduced the RANKL-induced expression of osteoclastic marker genes.•Moreover, SG attenuated RANKL-induced MAPKs and NF-κB activation.
Inflammatory cytokines play a major role in osteoclastogenesis, leading to the bone resorption that is frequently associated with osteoporosis. Sargachromanol G (SG), isolated from the brown alga Sargassum siliquastrum, inhibits the production of inflammatory cytokines. In the present study, we determined the effect of SG on receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation. SG inhibited RANKL-induced osteoclast differentiation from RAW264.7 cells without signs of cytotoxicity. Additionally, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), matrix metalloproteinase 9 (MMP9), and calcitonin receptor (CTR), was strongly inhibited. SG inhibited RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκB-α degradation. Furthermore, SG inhibited RANKL-induced phosphorylation of mitogen activated protein kinases (p38, JNK, and ERK). This study identified SG as an inhibitor for osteoclast formation and provided evidence that natural compounds, such as SG, are an alternative medicines for preventing and treating osteolysis. |
| doi_str_mv | 10.1016/j.bbrc.2013.04.046 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1732829168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X13006724</els_id><sourcerecordid>1732829168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-c9a3b2822c4ff51036ca504bb6c2e559a582152ed61a19e545b9cb5772e927e43</originalsourceid><addsrcrecordid>eNqFkc2KFDEQx4Mo7rj6Ah4kRy_dm49OugNexsVdlx1X8QO9hSRdM5NhpjOmuhcWfDIfwmcyw6weFQqKgl_9KOpPyHPOas64PtvU3udQC8ZlzZpS-gGZcWZYJThrHpIZY0xXwvBvJ-QJ4oYxzhttHpMTITXnbatn5Mcnl1curHPauSFt6SWNwzr6OCJNOEIKW4djWsEAGJH6O4rTfp8BMQ4rOq6BujDGWzfGNNCbi-rXz9fUDT19N_9wjUVFP85vrhdVHPopQF-mr1Topm5pgO0Wn5JHS7dFeHbfT8mXizefz99Wi_eXV-fzRRVkZ8YqGCe96IQIzXKpOJM6OMUa73UQoJRxqhNcCeg1d9yAapQ3wau2FWBEC408JS-P3n1O3yfA0e4iHi5wA6QJLW9l0Ruuu_-jUmnZtV0nCyqOaMgJMcPS7nPcuXxnObOHgOzGHgKyh4Asa0rpsvTi3j_5HfR_V_4kUoBXRwDKQ24jZIshwlC-FzOE0fYp_sv_G6c1oLo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356387883</pqid></control><display><type>article</type><title>Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Yoon, Weon-Jong ; Kim, Kil-Nam ; Heo, Soo-Jin ; Han, Sang-Chul ; Kim, Jihyeon ; Ko, Yeong-Jong ; Kang, Hee-Kyoung ; Yoo, Eun-Sook</creator><creatorcontrib>Yoon, Weon-Jong ; Kim, Kil-Nam ; Heo, Soo-Jin ; Han, Sang-Chul ; Kim, Jihyeon ; Ko, Yeong-Jong ; Kang, Hee-Kyoung ; Yoo, Eun-Sook</creatorcontrib><description>•We study the anti-ostoclastogenesis effect of SG in RANKL-activated RAW 264.7 cells.•SG inhibits osteoclastogenesis from macrophages in vitro.•SG also reduced the RANKL-induced expression of osteoclastic marker genes.•Moreover, SG attenuated RANKL-induced MAPKs and NF-κB activation.
Inflammatory cytokines play a major role in osteoclastogenesis, leading to the bone resorption that is frequently associated with osteoporosis. Sargachromanol G (SG), isolated from the brown alga Sargassum siliquastrum, inhibits the production of inflammatory cytokines. In the present study, we determined the effect of SG on receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation. SG inhibited RANKL-induced osteoclast differentiation from RAW264.7 cells without signs of cytotoxicity. Additionally, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), matrix metalloproteinase 9 (MMP9), and calcitonin receptor (CTR), was strongly inhibited. SG inhibited RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκB-α degradation. Furthermore, SG inhibited RANKL-induced phosphorylation of mitogen activated protein kinases (p38, JNK, and ERK). This study identified SG as an inhibitor for osteoclast formation and provided evidence that natural compounds, such as SG, are an alternative medicines for preventing and treating osteolysis.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2013.04.046</identifier><identifier>PMID: 23611776</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acid Phosphatase - genetics ; Acid Phosphatase - metabolism ; Animals ; Benzopyrans - pharmacology ; Cathepsin K - genetics ; Cathepsin K - metabolism ; Cell Line ; Cell Survival - drug effects ; Dose-Response Relationship, Drug ; Gene Expression - drug effects ; I-kappa B Proteins - metabolism ; Immunoblotting ; Isoenzymes - genetics ; Isoenzymes - metabolism ; Macrophages - cytology ; Macrophages - drug effects ; Macrophages - metabolism ; MAPK ; Matrix Metalloproteinase 9 - genetics ; Matrix Metalloproteinase 9 - metabolism ; Mice ; Mitogen-Activated Protein Kinase 8 - metabolism ; Mitogen-Activated Protein Kinases - metabolism ; NF-kappa B - metabolism ; NF-KappaB Inhibitor alpha ; NF-κB ; Osteoclastogenesis ; Osteoclastogenic marker gene ; Osteoclasts - cytology ; Osteoclasts - drug effects ; Osteoclasts - metabolism ; p38 Mitogen-Activated Protein Kinases - metabolism ; Phosphorylation - drug effects ; RANK Ligand - pharmacology ; RANKL ; Receptors, Calcitonin - genetics ; Receptors, Calcitonin - metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Sagachromanol G (SG) ; Sargassum siliquastrum ; Tartrate-Resistant Acid Phosphatase</subject><ispartof>Biochemical and biophysical research communications, 2013-05, Vol.434 (4), p.892-897</ispartof><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-c9a3b2822c4ff51036ca504bb6c2e559a582152ed61a19e545b9cb5772e927e43</citedby><cites>FETCH-LOGICAL-c389t-c9a3b2822c4ff51036ca504bb6c2e559a582152ed61a19e545b9cb5772e927e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbrc.2013.04.046$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23611776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoon, Weon-Jong</creatorcontrib><creatorcontrib>Kim, Kil-Nam</creatorcontrib><creatorcontrib>Heo, Soo-Jin</creatorcontrib><creatorcontrib>Han, Sang-Chul</creatorcontrib><creatorcontrib>Kim, Jihyeon</creatorcontrib><creatorcontrib>Ko, Yeong-Jong</creatorcontrib><creatorcontrib>Kang, Hee-Kyoung</creatorcontrib><creatorcontrib>Yoo, Eun-Sook</creatorcontrib><title>Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>•We study the anti-ostoclastogenesis effect of SG in RANKL-activated RAW 264.7 cells.•SG inhibits osteoclastogenesis from macrophages in vitro.•SG also reduced the RANKL-induced expression of osteoclastic marker genes.•Moreover, SG attenuated RANKL-induced MAPKs and NF-κB activation.
Inflammatory cytokines play a major role in osteoclastogenesis, leading to the bone resorption that is frequently associated with osteoporosis. Sargachromanol G (SG), isolated from the brown alga Sargassum siliquastrum, inhibits the production of inflammatory cytokines. In the present study, we determined the effect of SG on receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation. SG inhibited RANKL-induced osteoclast differentiation from RAW264.7 cells without signs of cytotoxicity. Additionally, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), matrix metalloproteinase 9 (MMP9), and calcitonin receptor (CTR), was strongly inhibited. SG inhibited RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκB-α degradation. Furthermore, SG inhibited RANKL-induced phosphorylation of mitogen activated protein kinases (p38, JNK, and ERK). This study identified SG as an inhibitor for osteoclast formation and provided evidence that natural compounds, such as SG, are an alternative medicines for preventing and treating osteolysis.</description><subject>Acid Phosphatase - genetics</subject><subject>Acid Phosphatase - metabolism</subject><subject>Animals</subject><subject>Benzopyrans - pharmacology</subject><subject>Cathepsin K - genetics</subject><subject>Cathepsin K - metabolism</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Gene Expression - drug effects</subject><subject>I-kappa B Proteins - metabolism</subject><subject>Immunoblotting</subject><subject>Isoenzymes - genetics</subject><subject>Isoenzymes - metabolism</subject><subject>Macrophages - cytology</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>MAPK</subject><subject>Matrix Metalloproteinase 9 - genetics</subject><subject>Matrix Metalloproteinase 9 - metabolism</subject><subject>Mice</subject><subject>Mitogen-Activated Protein Kinase 8 - metabolism</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>NF-kappa B - metabolism</subject><subject>NF-KappaB Inhibitor alpha</subject><subject>NF-κB</subject><subject>Osteoclastogenesis</subject><subject>Osteoclastogenic marker gene</subject><subject>Osteoclasts - cytology</subject><subject>Osteoclasts - drug effects</subject><subject>Osteoclasts - metabolism</subject><subject>p38 Mitogen-Activated Protein Kinases - metabolism</subject><subject>Phosphorylation - drug effects</subject><subject>RANK Ligand - pharmacology</subject><subject>RANKL</subject><subject>Receptors, Calcitonin - genetics</subject><subject>Receptors, Calcitonin - metabolism</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Sagachromanol G (SG)</subject><subject>Sargassum siliquastrum</subject><subject>Tartrate-Resistant Acid Phosphatase</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2KFDEQx4Mo7rj6Ah4kRy_dm49OugNexsVdlx1X8QO9hSRdM5NhpjOmuhcWfDIfwmcyw6weFQqKgl_9KOpPyHPOas64PtvU3udQC8ZlzZpS-gGZcWZYJThrHpIZY0xXwvBvJ-QJ4oYxzhttHpMTITXnbatn5Mcnl1curHPauSFt6SWNwzr6OCJNOEIKW4djWsEAGJH6O4rTfp8BMQ4rOq6BujDGWzfGNNCbi-rXz9fUDT19N_9wjUVFP85vrhdVHPopQF-mr1Topm5pgO0Wn5JHS7dFeHbfT8mXizefz99Wi_eXV-fzRRVkZ8YqGCe96IQIzXKpOJM6OMUa73UQoJRxqhNcCeg1d9yAapQ3wau2FWBEC408JS-P3n1O3yfA0e4iHi5wA6QJLW9l0Ruuu_-jUmnZtV0nCyqOaMgJMcPS7nPcuXxnObOHgOzGHgKyh4Asa0rpsvTi3j_5HfR_V_4kUoBXRwDKQ24jZIshwlC-FzOE0fYp_sv_G6c1oLo</recordid><startdate>20130517</startdate><enddate>20130517</enddate><creator>Yoon, Weon-Jong</creator><creator>Kim, Kil-Nam</creator><creator>Heo, Soo-Jin</creator><creator>Han, Sang-Chul</creator><creator>Kim, Jihyeon</creator><creator>Ko, Yeong-Jong</creator><creator>Kang, Hee-Kyoung</creator><creator>Yoo, Eun-Sook</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>20130517</creationdate><title>Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells</title><author>Yoon, Weon-Jong ; Kim, Kil-Nam ; Heo, Soo-Jin ; Han, Sang-Chul ; Kim, Jihyeon ; Ko, Yeong-Jong ; Kang, Hee-Kyoung ; Yoo, Eun-Sook</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-c9a3b2822c4ff51036ca504bb6c2e559a582152ed61a19e545b9cb5772e927e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acid Phosphatase - genetics</topic><topic>Acid Phosphatase - metabolism</topic><topic>Animals</topic><topic>Benzopyrans - pharmacology</topic><topic>Cathepsin K - genetics</topic><topic>Cathepsin K - metabolism</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Gene Expression - drug effects</topic><topic>I-kappa B Proteins - metabolism</topic><topic>Immunoblotting</topic><topic>Isoenzymes - genetics</topic><topic>Isoenzymes - metabolism</topic><topic>Macrophages - cytology</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>MAPK</topic><topic>Matrix Metalloproteinase 9 - genetics</topic><topic>Matrix Metalloproteinase 9 - metabolism</topic><topic>Mice</topic><topic>Mitogen-Activated Protein Kinase 8 - metabolism</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>NF-kappa B - metabolism</topic><topic>NF-KappaB Inhibitor alpha</topic><topic>NF-κB</topic><topic>Osteoclastogenesis</topic><topic>Osteoclastogenic marker gene</topic><topic>Osteoclasts - cytology</topic><topic>Osteoclasts - drug effects</topic><topic>Osteoclasts - metabolism</topic><topic>p38 Mitogen-Activated Protein Kinases - metabolism</topic><topic>Phosphorylation - drug effects</topic><topic>RANK Ligand - pharmacology</topic><topic>RANKL</topic><topic>Receptors, Calcitonin - genetics</topic><topic>Receptors, Calcitonin - metabolism</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Sagachromanol G (SG)</topic><topic>Sargassum siliquastrum</topic><topic>Tartrate-Resistant Acid Phosphatase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoon, Weon-Jong</creatorcontrib><creatorcontrib>Kim, Kil-Nam</creatorcontrib><creatorcontrib>Heo, Soo-Jin</creatorcontrib><creatorcontrib>Han, Sang-Chul</creatorcontrib><creatorcontrib>Kim, Jihyeon</creatorcontrib><creatorcontrib>Ko, Yeong-Jong</creatorcontrib><creatorcontrib>Kang, Hee-Kyoung</creatorcontrib><creatorcontrib>Yoo, Eun-Sook</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoon, Weon-Jong</au><au>Kim, Kil-Nam</au><au>Heo, Soo-Jin</au><au>Han, Sang-Chul</au><au>Kim, Jihyeon</au><au>Ko, Yeong-Jong</au><au>Kang, Hee-Kyoung</au><au>Yoo, Eun-Sook</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2013-05-17</date><risdate>2013</risdate><volume>434</volume><issue>4</issue><spage>892</spage><epage>897</epage><pages>892-897</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>•We study the anti-ostoclastogenesis effect of SG in RANKL-activated RAW 264.7 cells.•SG inhibits osteoclastogenesis from macrophages in vitro.•SG also reduced the RANKL-induced expression of osteoclastic marker genes.•Moreover, SG attenuated RANKL-induced MAPKs and NF-κB activation.
Inflammatory cytokines play a major role in osteoclastogenesis, leading to the bone resorption that is frequently associated with osteoporosis. Sargachromanol G (SG), isolated from the brown alga Sargassum siliquastrum, inhibits the production of inflammatory cytokines. In the present study, we determined the effect of SG on receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation. SG inhibited RANKL-induced osteoclast differentiation from RAW264.7 cells without signs of cytotoxicity. Additionally, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), matrix metalloproteinase 9 (MMP9), and calcitonin receptor (CTR), was strongly inhibited. SG inhibited RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκB-α degradation. Furthermore, SG inhibited RANKL-induced phosphorylation of mitogen activated protein kinases (p38, JNK, and ERK). This study identified SG as an inhibitor for osteoclast formation and provided evidence that natural compounds, such as SG, are an alternative medicines for preventing and treating osteolysis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23611776</pmid><doi>10.1016/j.bbrc.2013.04.046</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-291X |
| ispartof | Biochemical and biophysical research communications, 2013-05, Vol.434 (4), p.892-897 |
| issn | 0006-291X 1090-2104 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1732829168 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Acid Phosphatase - genetics Acid Phosphatase - metabolism Animals Benzopyrans - pharmacology Cathepsin K - genetics Cathepsin K - metabolism Cell Line Cell Survival - drug effects Dose-Response Relationship, Drug Gene Expression - drug effects I-kappa B Proteins - metabolism Immunoblotting Isoenzymes - genetics Isoenzymes - metabolism Macrophages - cytology Macrophages - drug effects Macrophages - metabolism MAPK Matrix Metalloproteinase 9 - genetics Matrix Metalloproteinase 9 - metabolism Mice Mitogen-Activated Protein Kinase 8 - metabolism Mitogen-Activated Protein Kinases - metabolism NF-kappa B - metabolism NF-KappaB Inhibitor alpha NF-κB Osteoclastogenesis Osteoclastogenic marker gene Osteoclasts - cytology Osteoclasts - drug effects Osteoclasts - metabolism p38 Mitogen-Activated Protein Kinases - metabolism Phosphorylation - drug effects RANK Ligand - pharmacology RANKL Receptors, Calcitonin - genetics Receptors, Calcitonin - metabolism Reverse Transcriptase Polymerase Chain Reaction Sagachromanol G (SG) Sargassum siliquastrum Tartrate-Resistant Acid Phosphatase |
| title | Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A00%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sargachromanol%20G%20inhibits%20osteoclastogenesis%20by%20suppressing%20the%20activation%20NF-%CE%BAB%20and%20MAPKs%20in%20RANKL-induced%20RAW%20264.7%20cells&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Yoon,%20Weon-Jong&rft.date=2013-05-17&rft.volume=434&rft.issue=4&rft.spage=892&rft.epage=897&rft.pages=892-897&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2013.04.046&rft_dat=%3Cproquest_cross%3E1732829168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356387883&rft_id=info:pmid/23611776&rft_els_id=S0006291X13006724&rfr_iscdi=true |